Contact

Skip to main content Flight Meridian Home About Services Contact Aviation readiness · evidence-first context Ibogaine for Air Force Pilots A careful look at policy, safety, evidence, and the care pathways that matter when military aviation readiness is at stake. Start with policy Talk through safeguards Primary operational point Schedule I status, cardiac risk, and flight standards make this a policy-sensitive issue for aircrew. On this page What it is and how it works Legal status and policy Aircrew regulations Safety and cardiac risk Flight readiness Evidence for PTSD, TBI, addiction International availability Operational risk Approved alternatives Confidential care Questions answered This independent resource consolidates what active-duty and guard/reserve Air Force communities need to know about ibogaine, with emphasis on regulatory compliance, aeromedical safety, and mission risk. It addresses Department of Defense policy, USAF flying standards, and the realities facing pilots and aircrew navigating PTSD, TBI, addiction, and depression. Core concepts what is ibogaine and how it works Ibogaine is a psychoactive alkaloid derived from Tabernanthe iboga. Interest grew because some observational studies report reductions in withdrawal and craving in opioid use disorder, alongside changes in PTSD symptom clusters. Its multimodal pharmacology means multiple targets likely contribute to effect, but that same complexity raises safety and aeromedical concerns for pilots and aircrew. The mechanism of action remains incompletely mapped. Proposed elements include NMDA receptor antagonism, sigma-1 modulation, kappa opioid activity, and modest serotonin reuptake inhibition. After ingestion, CYP2D6 metabolism converts ibogaine into noribogaine, a metabolite with a substantially longer half-life that can extend physiologic effects for days. That prolonged tail is vital in aviation risk management, because even subtle vestibular dysfunction or fatigue can impair cockpit performa

Contact

Independent by design.